Vaginal infections:

Indications for: BREXAFEMME

Vulvovaginal candidiasis.

Adult Dosage:

≥18yrs or post-menarchal: 300mg orally every 12hrs for 1 day. Concomitant strong CYP3A4 inhibitors: 150mg orally every 12hrs for 1 day.

Children Dosage:

<18yrs or pre-menarchal: not established.

BREXAFEMME Contraindications:


BREXAFEMME Warnings/Precautions:

Severe hepatic impairment: not studied. Risk of fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 4 days after the last dose. Exclude pregnancy status prior to initiation. Nursing mothers.

BREXAFEMME Classification:

Triterpenoid antifungal.

BREXAFEMME Interactions:

Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole); reduce ibrexafungerp dose. May be antagonized by strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John’s wort, long acting barbiturates, bosentan, efavirenz, etravirine); avoid concomitant use.

Adverse Reactions:

Diarrhea, nausea, abdominal pain, dizziness, vomiting.

Generic Drug Availability:


How Supplied:

Blister packs—4

Pricing for BREXAFEMME

4 tablets of 150mg carton (Qty: 1)
Appx. price $498